JPMorgan Urges Investors to Capitalize on Market Dips Amid Global Volatility
JPMorgan recommends buying market dips, highlighting strong earnings growth, controlled inflation, and emerging markets trading at...
Somnigroup Acquires Leggett & Platt (LEG) in $2.5B All-Stock Transaction
Leggett & Platt (LEG) stock surges 5.7% as Somnigroup (SGI) confirms $2.5B all-stock takeover deal expected to close by late 2026....
T-Mobile (TMUS) Stock Climbs on KeyBanc Analyst Upgrade: 33% Gain Projected
KeyBanc upgrades T-Mobile (TMUS) to Overweight with $260 target, suggesting 33% upside potential based on compressed valuation and...
Bittensor Price Prediction Faces Governance Crisis While Pepeto Collects $8.9M a...
The bittensor price prediction that looked like a recovery story last week now carries a trust problem no chart pattern can fix. A...
WLFI mints $25 million in fresh USD1 and burns $3 million, days after repayment...
The mint and a simultaneous $3 million burn come days after the venture said it had repaid $25 million of the borrowing position t...
World Liberty Financial executes a massive $22 million stablecoin shuffle amid i...
The mint and a simultaneous $3 million burn come days after the venture said it had repaid $25 million of the borrowing position t...
Trump Orders Naval Blockade of Strait of Hormuz: Markets Tumble as Oil Surges Pa...
Stock futures dropped and oil prices surged above $100 after Trump ordered a naval blockade of the Strait of Hormuz. Iran vows ret...
StarkWare cuts staff in push toward revenue-generating products
StarkWare CEO Eli Ben-Sasson said the company will split into two units as it adopts a faster and leaner “startup mode.”Zero-knowl...
Goldman Sachs (GS) Stock Surges on Strong Q1 Results and Record Equities Trading
Goldman Sachs (GS) stock rallies after reporting Q1 earnings of $5.63B, up 19%. Record equities revenue and investment banking fee...
IDEAYA Biosciences (IDYA) Soars 26% on Breakthrough Eye Cancer Trial Data
IDEAYA Biosciences (IDYA) stock jumped 26% after its eye cancer drug combo doubled progression-free survival in a Phase 2/3 trial...